David J. Hermann

Next Generation TB Drug Combinations from the Pan-TB Consortium: Combination Efficacy and Contributions of Individual Agents, Evaluated in a BALB/c Mouse TB Model

The paper evaluates next-generation TB drug combinations in a mouse model, showing some regimens cure 90% of mice in under 2 months with faster sterilizing efficacy than existing treatments.

Nonclinical pharmacokinetics and relative efficacy of the first 25 novel tuberculosis drug combinations from the PAN-TB consortium: Use of the BALB/c relapsing mouse model and combination pharmacokinetics within a modeling-based framework

The paper evaluates 25 tuberculosis drug combinations in a mouse model, finding 15 combinations with T90 <5 months and three top combinations curing 90% of mice in <3 months.

A Stochastic Simulation-Based Approach to Inform Relapsing Mouse Model (RMM) Study Design for Non-Clinical Assessment of Tuberculosis

This paper evaluates alternative study designs for relapsing mouse models of tuberculosis to reduce animal use while maintaining accuracy in estimating treatment efficacy.

A modeling-based framework to evaluate forgiveness of TB drug combinations in a BALB/c relapsing mouse model.

This study evaluates the forgiveness of TB drug combinations using a mouse model, finding BPaMZ is more forgiving of missed doses than RHZE/RH.